AIMS: Oestrogen receptor beta (ERbeta) is present in breast tumours, although its prognostic and pathophysiological roles remain to be established. METHODS: Standard immunohistochemistry with a specific monoclonal antibody was performed on paraffin wax embedded sections; 10% of strongly immunostained carcinoma cells was used as the cutoff point to classify tumours as ERbeta positive. Statistical correlations were sought with clinicopathological variables (including hormone receptor status) and disease free (DFS) and overall survival (OS) in a well documented series of 181 invasive breast carcinomas. Cell proliferation was assessed immunohistochemically by topoisomerase IIa (TopoIIa) index; p53 protein accumulation and c-erbB-2 oncoprotein expression were also taken into account. RESULTS: ERbeta immunoreactivity was detected in most specimens (71.2%); it was positively linked to ERalpha immunoreactivity and increased TopoIIalpha index, and inversely to c-erbB-2 overexpression. There were no correlations with p53 immunostaining or other clinicopathological parameters. A significant favourable impact of ERbeta immunopositivity emerged with regard to DFS and OS in both univariate and multivariate analysis; ERbeta immunopositivity retained its favourable significance with regard to DFS in the subgroups of stage I and II patients when they were examined separately. Progesterone receptor expression also had an independent favourable influence on survival, albeit with less significance. In contrast, survival was not significantly influenced by ERalpha status. CONCLUSIONS: Because of the positive association between ERbeta immunoreactivity and TopoIIalpha expression, the presence of ERbeta in breast cancer cells could be considered an indication of increased proliferation. Nevertheless, ERbeta immunoreactivity emerges as a valuable, independent indicator of favourable prognosis.
AIMS: Oestrogen receptor beta (ERbeta) is present in breast tumours, although its prognostic and pathophysiological roles remain to be established. METHODS: Standard immunohistochemistry with a specific monoclonal antibody was performed on paraffin wax embedded sections; 10% of strongly immunostained carcinoma cells was used as the cutoff point to classify tumours as ERbeta positive. Statistical correlations were sought with clinicopathological variables (including hormone receptor status) and disease free (DFS) and overall survival (OS) in a well documented series of 181 invasive breast carcinomas. Cell proliferation was assessed immunohistochemically by topoisomerase IIa (TopoIIa) index; p53 protein accumulation and c-erbB-2 oncoprotein expression were also taken into account. RESULTS:ERbeta immunoreactivity was detected in most specimens (71.2%); it was positively linked to ERalpha immunoreactivity and increased TopoIIalpha index, and inversely to c-erbB-2 overexpression. There were no correlations with p53 immunostaining or other clinicopathological parameters. A significant favourable impact of ERbeta immunopositivity emerged with regard to DFS and OS in both univariate and multivariate analysis; ERbeta immunopositivity retained its favourable significance with regard to DFS in the subgroups of stage I and II patients when they were examined separately. Progesterone receptor expression also had an independent favourable influence on survival, albeit with less significance. In contrast, survival was not significantly influenced by ERalpha status. CONCLUSIONS: Because of the positive association between ERbeta immunoreactivity and TopoIIalpha expression, the presence of ERbeta in breast cancer cells could be considered an indication of increased proliferation. Nevertheless, ERbeta immunoreactivity emerges as a valuable, independent indicator of favourable prognosis.
Authors: L Nakopoulou; A Zervas; A C Lazaris; C Constantinides; C Stravodimos; P Davaris; C Dimopoulos Journal: J Clin Pathol Date: 2001-04 Impact factor: 3.411
Authors: Y Omoto; S Inoue; S Ogawa; T Toyama; H Yamashita; M Muramatsu; S Kobayashi; H Iwase Journal: Cancer Lett Date: 2001-02-26 Impact factor: 8.679
Authors: P Rudolph; H Olsson; G Bonatz; V Ratjen; H Bolte; B Baldetorp; M Fernö; R Parwaresch; P Alm Journal: J Pathol Date: 1999-01 Impact factor: 7.996
Authors: P L Fitzgibbons; D L Page; D Weaver; A D Thor; D C Allred; G M Clark; S G Ruby; F O'Malley; J F Simpson; J L Connolly; D F Hayes; S B Edge; A Lichter; S J Schnitt Journal: Arch Pathol Lab Med Date: 2000-07 Impact factor: 5.534
Authors: L Nakopoulou; A C Lazaris; N Kavantzas; P Alexandrou; P Athanassiadou; A Keramopoulos; P Davaris Journal: Pathobiology Date: 2000 May-Jun Impact factor: 4.342
Authors: Nuiki Iota Chantzi; Marina Palaiologou; Artemis Stylianidou; Nikos Goutas; Stamatis Vassilaros; Helen P Kourea; Eugen Dhimolea; Dimitra J Mitsiou; Dina G Tiniakos; Muichael N Alexis Journal: J Cancer Res Clin Oncol Date: 2014-03-27 Impact factor: 4.553
Authors: Jae Hak Lee; Olaf Peters; Lutz Lehmann; Carmen S Dence; Terry L Sharp; Kathryn E Carlson; Dong Zhou; M Jeyakumar; Michael J Welch; John A Katzenellenbogen Journal: Nucl Med Biol Date: 2012-06-30 Impact factor: 2.408
Authors: John R Hawse; Jodi M Carter; Kirsten G M Aspros; Elizabeth S Bruinsma; Justin W Koepplin; Vivian Negron; Malayannan Subramaniam; James N Ingle; Karen L Rech; Matthew P Goetz Journal: Breast Cancer Res Treat Date: 2019-09-30 Impact factor: 4.872